# A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

> **NCT05365581** · PHASE1 · RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 398 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Pancreatic Adenocarcinoma

## Interventions

- **DRUG:** ASP2138
- **DRUG:** Pembrolizumab
- **DRUG:** Oxaliplatin
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Ramucirumab
- **DRUG:** Paclitaxel
- **DRUG:** Irinotecan
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT05365581
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-07
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05365581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05365581, "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05365581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*